Liminatus Pharma, Inc. (LIMN)
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
- Ticker
- LIMN
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $3.03M
- 52-week range
- $2.40 - $141.50
Valuation
- Share price
- $2.68 (close of Nov 18, 2026)
- P/E (TTM)
- -0.13x
- Price to book
- 10.09x
- Price to free cash flow
- -0.76x
- Enterprise value
- $4.48M
- Book value per share
- $0.27
Price performance
| Period | Change |
|---|---|
| 1 day | -4.63% |
| 5 days | -8.84% |
| 1 month | -11.84% |
| 3 months | -58.77% |
| 6 months | -71.34% |
| Year to date | -91.21% |
| 1 year | -95.17% |
| All time | -99.33% |
Short interest
- As of
- Oct 30, 2026
- Short % of float
- 4.43%
- Shares short
- 47.91K
- Days to cover
- 1.65
- Change since prior report
- +20.89%
- Source
- FINRA consolidated short interest
Profitability and growth
- Return on capital employed
- 30.33%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -131.39%
- Current ratio
- 1.12x
- Net debt to EBITDA
- -0.12x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- EBITDA
- -$2.97M
- Net income
- -$10.21M
- Interest expense
- $215.90K
Income statement by year
| Period end | Net income |
|---|---|
| 2025-12-31 | -$10.21M |
| 2024-12-31 | -$3.55M |
Free cash flow by year
| Period end | Free cash flow |
|---|---|
| 2025-12-31 | -$9.98M |
| 2024-12-31 | -$1.45M |
Investor relations
Next earnings report
- Next confirmed report
- Nov 19, 2026
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-11-12 | Sep 2026 | - |
| 2026-08-14 | Jun 2026 | - |
| 2026-05-15 | Mar 2026 | - |
| 2026-03-31 | Dec 2025 | - |
| 2025-11-13 | Sep 2025 | - |
| 2025-10-03 | Jun 2025 | - |
Filings and sources
- Company website
- liminatuspharma.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades